<div id="readability-page-1"><div><p>(MT Newswires) -- HOB Biotech's (SHA:688656) Shanghai subsidiary and Immunotek completed enrollment and dosing for the phase 3 clinical trial of its MM09 sublingual desensitization spray, according to a Thursday filing with the Shanghai Stock Exchange.</p><p> The multicenter phase 3 clinical trial targets allergies from house dust mites and dust mites, the filing said.</p><p> The company has also obtained import permits for the drug for indications for cat and dog hair and house dust mite allergens in both Hong Kong and Macao, the filing said.</p><p>Shares rose 1% during late afternoon trading on Wednesday.</p></div></div>

浩歐博

<p>浩歐博在上海的子公司已為其針對塵蟎過敏的 MM09 舌下脱敏噴霧劑的第三階段臨牀試驗招募了首位患者。該公司還獲得了在香港和澳門針對貓狗毛過敏原的藥物進口許可證。此消息發佈後，週三下午的交易中，股價上漲了 1%</p>

浩歐博上海子公司為抗過敏產品的臨牀試驗招募了首位患者